Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis

被引：0

作者：

Hee-Young Yoon

Jung Jin Hwang

Dong Soon Kim

Jin Woo Song

机构：

[1] University of Ulsan College of Medicine,Departments of Pulmonary and Critical Care Medicine, Asan Medical Center

[2] University of Ulsan College of Medicine,Department of Convergence Medicine, Asan Medical Center

来源：

Orphanet Journal of Rare Diseases | / 13卷

关键词：

Lymphangioleiomyomatosis; Sirolimus; Low dose; Respiratory function tests; Treatment outcome;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 157 条

[1]

Henske EP(2012)Lymphangioleiomyomatosis - a wolf in sheep's clothing J Clin Invest 122 3807-3816

[2]

McCormack FX(2015)The changing face of a rare disease: lymphangioleiomyomatosis Eur Respir J 46 1471-1485

[3]

Harari S(2011)Lymphangioleiomyomatosis: what do we know and what are we looking for? Eur Respir Rev 20 34-44

[4]

Torre O(2008)Lymphangioleiomyomatosis: a clinical update Chest 133 507-516

[5]

Cassandro R(2008)Rapamycin and mTOR kinase inhibitors J Chem Biol 1 27-36

[6]

Moss J(2002)Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors Cancer Res 62 5645-5650

[7]

Harari S(2005)Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models Genes, chromosomes & cancer 42 213-227

[8]

Torre O(2011)mTORC2 is required for proliferation and survival of TSC2-null cells Mol Cell Biol 31 2484-2498

[9]

Moss J(2008)Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis N Engl J Med 358 140-151

[10]

McCormack FX(2011)Efficacy and safety of sirolimus in lymphangioleiomyomatosis N Engl J Med 364 1595-1606